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Abstract.  Antibodies with epitopes near the heavy 
meromyosin/light meromyosin junction distinguish the 
folded from the extended conformational states of 
smooth muscle myosin. Antibody 10S.1 has  100-fold 
higher avidity for folded than for extended myosin, 
while antibody S2.2 binds preferentially to the ex- 
tended state. The properties of these antibodies pro- 
vide direct evidence that the conformation of the rod 
is different in the folded than the extended monomeric 
state, and suggest that this perturbation may extend 
into the subfragment 2  region of the rod. Two antihead 
antibodies with epitopes on the heavy chain map at or 
near the head/rod junction. Magnesium greatly en- 
hances the binding of these antibodies to myosin, 
showing that the conformation of the heavy chain in 
the neck region changes upon divalent cation binding 
to the regulatory light chain. Myosin assembly is also 
altered by antibody binding. Antibodies that bind to 
the central region of the rod block disassembly of ilia- 
merits upon MgATP addition. Antibodies with epitopes 
near the COOH terminus of the rod, in contrast, pro- 
mote filament depolymerization, suggesting that this 
region of the tail is important for assembly. The 
monoctonal antibodies described here are therefore 
useful both for detecting and altering conformational 
states of smooth muscle myosin. 
T 
HE assembly of smooth muscle myosin in vitro is reg- 
ulated by light chain phosphorylation. In the presence 
of MgATP, dephosphorylated filaments are disassem- 
bled to a monomer in which the tail is folded into thirds. This 
assembly-incompetent conformation unfolds and  immedi- 
ately reassembles into filaments upon phosphorylation of the 
regulatory light chain (Suzuki  et al.,  1978; Trybus et ai., 
1982; Onishi  and Wakabayashi,  1982; Trybus and Lowey, 
1984). Although the dephosphorylated folded form of myo- 
sin is prevalent in vitro at salt concentrations and pH that ap- 
proximate physiological  conditions,  it is not known if this 
conformation of myosin exists in the cell. A goal of the pres- 
ent study was to produce an antibody that would react prefer- 
entially with the folded conformation  of  myosin. Of  the many 
monoclo.nal antibodies produced, two conformation-specific 
antirod antibodies  were identified.  One binds  with high 
avidity to folded myosin, while a second binds preferentially 
to extended myosin.  By reacting fixed muscle tissue  with 
these antibodies  it may be possible  to determine, by tech- 
niques such as immunogold labeling,  if the soluble folded 
form of myosin exists in a smooth muscle cell. 
Another region of myosin that undergoes large changes 
upon folding is the head/rod junction. In the bent form, the 
myosin heads are constrained in a downward orientation to- 
ward the tail (Onishi  and Wakabayashi,  1982; Trybus and 
Lowey,  1984).  The regulatory light chain, which plays a 
key role in the folded-to-extended conformational transition 
(Trybus and Lowey, 1988), has been localized to this region 
in both skeletal  and scallop myosin (Winkelmaan et al., 
1983;  Flicker et al.,  1983). Changes in the neck region 
may also be critical for determining the enzymatic activity 
of the smooth muscle myosin molecule, which is controlled 
by light chain phosphorylation. Two antihead antibodies, 
which bind to the heavy chain in this region, are sensitive 
to changes induced in the nearby phosphorylatable  regula- 
tory light chain. 
Monoclonal antibodies can also be used to stabilize myo- 
sin conformational states that would otherwise be inaccessi- 
ble for study in a particular solvent.  To compare the actin- 
activated activity of filamentous and monomeric myosin, for 
example,  antibodies  have been used to depolymerize fila- 
ments formed from Acanthamoeba (Kiehart and Pollard, 
1984) and Dictyostelium (Pagh and Gerisch, 1986) myosins. 
Dephosphorylated filaments  formed from smooth muscle 
myosin, in contrast, are unusually labile and disassemble to 
a folded monomer under conditions normally used to mea- 
sure actin-activated ATPases. Even copolymerizing dephos- 
phorylated myosin with phosphorylated myosin is insufficient 
to stabilize the dephosphorylated species in the filamentous 
form (Trybus and Lowey, 1987). Several antirod antibodies 
are described that stabilize dephosphorylated myosin in the 
filamentous form. These antibodies have made it possible to 
show that light chain phosphorylation is essential  for actin 
activation of  the enzymatic activity of myosin filaments (Try- 
bus,  1989). 
Materials and Methods 
Immunization Protocol and Production of 
Monoclonal Antibodies 
(C.B20 X  Balb.K)Fi mice were immunized with 100 ttg turkey gizzard 
myosin emulsified in complete Freund's adjuvant, which was administered 
both intraperitoneally  and injected into the foot pads. The myosin was Cross- 
linked to stabilize it in the folded monomeric coaformation (Trybus, and 
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boost with 50 #g of cross-linked folded  myosin  in PBS.  The mice were 
killed for fusion 4 d after the secondary boost. The spleen cells were fused 
with the hybrid myeloma cell line Sp2/0-Ag 14 (Shulman et al., 1978). The 
procedures used for fusion, subeloning of cell lines, and ascites production 
are described in detail in Winkelmann et al. (1983). 
The antibody designated as 10S.I is the only antibody described in this 
paper in which a pool of subclones was injected into mice for ascites produc- 
tion. This was necessary because of the extremely  slow growth properties 
of this cell line. Prolonged growth in culture, which was necessary to gener- 
ate enough cells for injection into mice, was inevitably accompanied by a 
change in the cells which made them stop secreting antimyosin  antibody and 
grow faster. Thus the strategy used for ascites production was to grow posi- 
tive subclones in 96-well plates instead of in large volume flasks, screen the 
wells by ELISA to identify and remove hybridomas that had stopped secret- 
ing the antibody of interest, and the same day inject cells from the positive 
wells into pristane-primed mice. It is likely, however, that the subclones are 
identical.  This antibody had two properties that made it easy to identify; 
i.e., an unusual isotype (IgG2a), and a much higher affinity for the folded 
conformation of myosin. 
Antibody Purification 
Antibodies were purified from ascitic fluid on an Affi-Gel Protein A MAPS 
U kit (Bio-Rad Laboratories, Richmond, CA) essentially as described by 
the manufacturer.  IgGl was eluted from the column at pH 6.0, IgG2a at pH 
4.5, and IgG2b at pH 3.5. Concentration of purified antibody was deter- 
mined using E(l%, 280 nm) =  14.5. 
Direct Binding ELISA 
Antibody binding to myosin or its fragments was determined by solid-phase 
ELISA.  The adsorption of antigen to the plate and the washing procedure 
between steps  was as described in Winkeimann et al.  (1983).  Antibody 
binding to antigen was detected with biotinylated anti-mouse IgG, followed 
by streptavidin-/~-galactosidase,  and the substrate p-nltrophenyl-/3-v-galac- 
topyranoside.  For screening of hybridomas, the secondary antibody was di- 
rectly coupled to ~-galactosidase  (Bethesda Research Laboratories, Gaith- 
ersburg, MD). Absorbance at 405 nm was read on a plate reader (model 
EL 308; Bio-Tek Instruments, Inc., Burlington, VT). Isotype-specific  anti- 
bodies were purchased from Boehringer Mannheim Biochemicals (Indi- 
anapolis, IN). 
Solution Competition ELISA 
A solution-competition  method is needed to quantitate relative affinities of 
the antibodies for different  conformationai states  of myosin.  A  constant 
amount of antibody was mixed with twofold serial dilutions of myosin, start- 
ing with ~0.2 mg/mi antigen. Folded myosin was prepared by adding I mM 
MgATP to myosin  in 10 mM KPi,  pH 7.5, 50 mM KC1, 5 mM MgCI2, 
1 mM EGTA,  1 mM DTT,  1 mM NAN3. Any filaments that did not de- 
polymerize were removed by centrifngation (100,000 g, 30 min). KCi was 
added to this soluble myosin to generate myosin in different conformational 
states at the same concentration. The antibody concentration in the compet- 
ing solution was that which gave half-maximal color by direct solid-phase 
ELISA, and was typically on the order of  0.1 ttg/ml. The competing solution 
also contained 0.5-1% BSA. The amount of free antibody in the antibody- 
antigen mixtures was determined by binding to the solid-phase antigen as 
in a direct ELISA. The solid-phase antigen was cross-linked folded myosin, 
because this species does not change conformation as a function of salt con- 
centration. The relative affinities of antibody for the antigen could be deter- 
mined from the amount of myosin in solution required to inhibit binding to 
the solid-phase antigen by 50%. Myosin concentration, determined using 
E(l%, 280 nm) =  5.0, was expressed as concentration of active sites; i.e., 
1 mg/ml myosin is 4 #M myosin. 
lmmunoblots 
SDS gels were run according to Laemmli (1970). Myosin and its fragments 
were  electrophoretically  transferred onto nitrocellulose (Towbin  ct al., 
1979). Antibody binding to antigen was detected with an anti-mouse anti- 
body coupled to horseradish peroxidase  or alkaline phosphatase (Bio-Rad 
Laboratories). Primary antibody concentration was ,'°5 ~g/ml. 
Immunoelectron Microscopy 
1 mg/ml myosin in 10 mM NaPi, pH 7.5, 0.4 M NaCI,  was incubated with 
0.3 mg/rnl antibody (equimolar ratio) for 15-30 min at room temperature. 
The myosin was diluted 100-fold into 0.5 M ammonium acetate,  pH 7.2, 
66% glycerol,  and rotary shadowed with platinum by the method of ~yler 
and Branton (1980) as described by Trybas and Lowey (1984). Electron mi- 
croscopy was performed on an electron microscope operated at 60 kV (EM 
301; Philips Electronic Instruments, Inc., Mahwah, NJ). For localization of 
10S.I,  1 mg/ml folded myosin and 0.3 mg/ml antibody were cross-linked 
together with 6 mg/mi dimethylsuberimidate for 3 h on ice before dilution 
into the shadowing buffer. The reaction was done in 20 mM KPi, pH 7.5, 
0.15 M KCI,  1 mM EGTA,  and stopped by removing excess cross-linker 
on a spun gel filtration column (Neal and Florini, 1973). 
Filament Pelleting  Assay 
Myosin filaments at 0.5 mg/ml (10 mM imidazole,  pH 7, 0.15 M NaCl, 5 
mM  MgCI2,  1 mM EGTA) were  incubated with 0.15  mg/ml antibody 
(equimolar ratio) for 10 rain at room temperature.  Antibody-myosin mix- 
tures in the presence or absence of 1 raM MgATP were pelleted in an airfuge 
(Beckman Instruments, Inc., Fnllerton, CA) for 10 min at 23 psi (130000 g). 
Equal amounts of  the supernatant and pellet were applied to SDS-polyacryl- 
amide gels. 
Protein Preparation 
Turkey gizzard myosin was prepared as described by Sellers et al. (1981). 
Rod and S1 were prepared by papain digestion (6 #g/ml, 15 min, room tem- 
perature) of 7 mg/ml myosin in 0.2 M ammonium acetate. Heavy meromyo- 
sin (HMM)  l and light meromyosin (LMM) were prepared by wchymo- 
tryptic digestion (10-50 #g/w_l, 15 min, room temperature) of 5  mg/ml 
myosin  in 10 mM NaPi,  pH 7.5, 0.5  M  NaCI,  1 mM EGTA.  Rod and 
LMM were purified by ethanol precipitation.  Papain SI (2 mg/ml in 10 mM 
imidazole,  pH 7.5, 40 mM NaCI,  1 mM DTT) was cleaved with trypsin- 
TPCK (10 #g/ml, 3 min, room temperature)  to generate the 29-, 50-, and 
25-kD tryptic head fragments (Marianne-Fopin et al.,  1983). 
Results 
Antihead Monoclonal Antibodies Detect Changes at 
the HeM~Rod Junction 
Of the 11 monoclonal antibodies produced against the heavy 
chain  of gizzard  smooth muscle myosin,  4  were directed 
against the head region of myosin (Table I and Fig.  1). Solid- 
phase ELISA showed that SI.1 through S1.4 reacted with my- 
osin, HMM, and subfragrnent  1 (S1), but not with rod, the 
20-kD regulatory light  chain,  or the  17-kD light chain.  A 
representative  example  of solid-phase  binding  for two of 
these antibodies,  S1.2 and S1.4, is shown in Fig. 2. 
An unusual feature of two of the antihead antibodies (SI.3 
and S1.4) was that they reacted with HMM and dephosphory- 
lated or phosphorylated myosin only in the presem~ of mag- 
nesium (Fig. 2, A and B). S1, in contrast, bound equally well 
under all conditions.  The regulatory light chain is presum- 
ably the site of divalent cation binding, but based on ELISAs, 
the epitopes for these antibodies reside on the heavy chain. 
The cor~n'mationally sensitive  nature of the site to which 
these antibodies bind is consistent with the observation that 
these antibodies do not react with myosin or its tryptic frag- 
ments in  immunoblots,  despite a  high  affinity  for native 
myosin in solution (Table I). Electron microscopy of metal- 
shadowed antibody-myosin complexes showed that both an- 
tibodies S1.3 and S1.4 mapped to the head/rod junction, yet 
had distinct  patterns of binding  and were therefore  unique 
antibodies (Fig.  3, A and B). 
The two antihead antibodies that do not show divalent cat- 
ion sensitivity  (SI.I and S1.2) bind to more distal regions of 
the head (Fig. 3, C and D). The epitope recognized by SI.1 
1.  Abbreviations used in this paper:  HMM and LMM,  heavy and light 
meromyosin,  respectively;  S1 and $2, subfrngments  1 and 2, respectively. 
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Antibodies 
Relative affinities* 
Clone  lmmunoglobulin  Folded  Folded  Extended 
Antibody  designation  isotype  dimer$  monomer§  monomerl 
107 M-I  107 M-t  107 M-t 
S 1.1  4F6.1  IgG 1  2  1  2 
SI.2  1A1.3  IgGl  90  70  180 
S1.3  5D1.1  IgGl  -  -  - 
SI.4  5E9.1  IgGl  36  10  8 
$2.11  6A3.4  IgG1  4  3  3 
$2.2  6Cll.2  IgG1  0.4  3  42 
10S. 1  5D11  IgG2a  14  10  ~0.1 
LMM. 1  3H9.1  IgG2b  5  5  5 
LMM.2  IA6.1  IgGl  8  8  18 
LMM.3  5D10.3  IgGl  -  -  - 
LMM.41  2E8.1  IgGl  17  17  17 
The antibodies are designated by their fragment specificity, followed by a num- 
ber which indicates the relative position of an epitope within a fragment. Anti- 
body 10S. 1 binds at the HMM/LMM hinge. The epitupe for antibody S1.1 was 
further localized to the NHrterminal 29-kD region of the myosin head. All of 
the antibodies react with both turkey and chicken gizzard myosin, but none 
cross react with chicken pectoralis skeletal myosin. All of the antibodies have 
x light chains. 
* The relative affinities  listed in this table are the reciprocals of the myosin 
concentrations required to inhibit binding to the solid-phase antigen, cross- 
linked folded myosin, by 50%  in a solution competition ELISA. 
$ 50 mM KCI. 
§ 150 mM KCI. 
II 60O ~  KCI. 
Cross reacts with bovine aorta smooth muscle myosin. 
lies  within  the  NH2-terminal  29-kD  region  of the heavy 
chain of the head, based on its pattern of reactivity with tryp- 
tic fragments in immunoblots (data not shown). The epitope 
for S1.2 must also have a conformational  component, be- 
cause it did not react well in blots but bound strongly to myo- 
sin in solution (Table I). 
Binding Sites of  Antirod Monoclonal Antibodies 
Specificity of antirod antibodies was determined by ELISA 
and immunoblots (data not shown), but electron microscopy 
of metal-shadowed antibody-myosin complexes allowed pre- 
cise localization of the sites where the antibodies bound. The 
epitopes for three antibodies clustered around the HMM/ 
LMM hinge,  located "-,50 nm from the head/rod junction. 
$2.1 and $2.2 (Fig. 3, Eand F) bound at the COOH-terminal 
end of the $2,  while LMM.1  bound to the NH2-terminal 
portion of LMM (Fig. 3 G). The remaining antirod antibod- 
ies were more equally spaced throughout the LMM region: 
LMM.2 binds halfway  between the tip of the tail  and the 
head/rod junction (Fig.  3 H), LMM.3 maps ,~40 nm from 
the end of the rod (Fig. 3 I), while LMM.4 binds to the very 
tip of the tail (Fig.  3 J). 
The affinity of these antibodies for myosin was high,  as 
could be seen from the high percentage of myosin molecules 
that bound antibody in fields of metal-shadowed  molecules, 
even at the low concentrations  required for metal shadowing 
(10 #g/ml).  Solution competition ELISAs provided a more 
quantitative  measure of the relative affinities of antibody for 
myosin (Table I), but in general the two methods agreed qual- 
itatively. 
The remaining  antirod antibody did not react with HMM 
or LMM by ELISA (Fig.  4 A). When the 200-kD myosin- 
heavy chain  was digested with  increasing  concentrations 
of a-chymotrypsin, reactivity with the antibody decreased 
(Fig. 4 B). Immunoblots of these digests showed weak bind- 
ing only to intact heavy chain,  strongly  suggesting that the 
epitope for this antibody, designated  10S.1, was at the HMM/ 
LMM junction.  By electron microscopy,  10S.1 bound to 
folded, but not extended,  myosin.  The number of myosin 
molecules with bound antibody was greatly increased if the 
antibody-folded  myosin complex was cross-linked in solu- 
tion  before rotary shadowing  (Fig.  3 K).  Antibody  10S.1 
binds at the hairpin bend of the folded monomeric conforma- 
tion, directly confirming that the epitope for 10S.1 is located 
near the HMM/LMM hinge. 
Antirod Antibodies Distinguish between the Folded 
and Extended Conformations of  Myosin 
Two of the antibodies that  mapped near the hinge  region 
showed  a  large  difference  in their  affinity  for folded and 
extended myosin,  when compared by solution competition 
ELISA. Antibody 10S.1 required 100-fold less folded myosin 
than  extended  myosin to inhibit  binding  to the solid-phase 
antigen by 50%, indicating that 10S.1 binds preferentially  to 
the folded conformation (Fig. 5 A). As a control to eliminate 
the possibility that the antibody-antigen interaction was ion- 
ic strength  dependent,  cross-linked folded myosin,  which 
cannot extend at high salt, was used as the competing antigen 
in solution. The concentration  of cross-linked folded myosin 
required to inhibit binding by 50 % remained constant as the 
salt concentration  was increased from 0.1 to 0.5 M KCI (Fig. 
5 A, right). These results  show that  10S.1 predominantly 
recognizes a conformation assumed only when the a-helical 
coiled coil bends. 
$2.2  showed  complementary behavior to that observed 
with 10S.1; i.e., an ,x,90-fold higher affinity for myosin in 
high  salt than  in low salt (Fig.  5 B). Control experiments 
with cross-linked folded myosin again  established  that the 
antibody-antigen reaction showed little ionic strength depen- 
dence when conformation remained constant.  These results 
suggest that the perturbation induced by folding may extend 
into the $2 region of the rod. 
LMM.1, which also mapped near the hinge region, showed 
no preferential  reaction With either conformation of myosin 
(Fig.  5 C).  $2.1,  which binds NH2 terminal  to $2.2, also 
did not distinguish  between conformations, indicating  that 
81.1 
$1.2  S2.2 
¢  ',: 
.3  10S.1  LMM.2 
$1.4 
I'='~S 1  -'--  :=  $2  =~=  LMM  =1 
~  HMM  -"-~ 
~=  ROD  =1 
Figure 1. Diagram indicating the approximate binding sites for the 
monoclonal antibodies described in this paper. The antibodies are 
designated by the region of myosin to which they bind (S1, $2, or 
LMM), followed  by a number which indicates the relative position 
of an epitope within a fragment. The numbers increase from the 
NH2 to the COOH terminal of a particular fragment. The antibody 
designated  10S.1  binds at the HMM/LMM  hinge. 
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Figure  2. Binding  of  antihead  antibodies  to  myosin  and  its  fragments  in  the  presence  or  absence  of  magnesium. (A  and  B) Antihcnd  antibody 
SI.4  reacted  with myosin (e),  HMM  (D),  and Sl (A),  but  not rod (4),  the  20-kD regulatory  light  chain  (o),  or  the 17-kD light  chain  (m) 
by direct  ELISA. An unusual  property  of  antibody  $1.4  is  that  binding  to  myosin and HMM  is seen  in  the  presence  of  magnesium (B), 
but not in  its  absence (,4).  Antibody $1.3  shows a similar  metal  ion  dependency (data  not shown). (C) SI.2  binds  to  myosin, HMM,  and 
SI independent  of  divalent  cations  (same symbols as in  A and B). SI.I  shows a similar  pattern  of  reactivity  (data  not shown). 
all of  the $2 region is not altered  upon folding.  Similarly, 
none of the other antihead or antirod antibodies showed a 
marked difference  in affinity  for myosin at low or high salt 
(Table I). 
Solution  competition ELISAs were done over  a much wider 
range of ionic strengths to determine the extent to which the 
antibodies  affected the  folded-to-extended conformational 
transition (Fig. 6). The arrows at the top of the figure show 
the ionic strengths at which the 6S extended monomer, the 
10S folded monomer, or the 15S folded dhner are formed 
(Trybus and Lowey, 1984). In the absence of antibody, myo- 
sin starts to unfold at >0.2 M KCI, and the transition is nearly 
complete by 0.25 M KCI. The affinity of 10S.I for myosin 
continued to decrease between 0.25 and 0.3 M KCI. This 
shift of the conformational  transition  to higher  salt in the 
presence of antibody indicates that antibody binding has to 
some extent stabilized the folded conformation. 
The affinity of $2.2 for extended myosin was constant and 
high above 0.3 M KCI (Fig. 6). The affinity decreased below 
this salt concentration as the myosin started to fold, reaching 
a minimum of 100,fold lower affinity at 50 mM KCI. Based 
only on this curve, however, it~is difficult to determine the 
relative affinities of $2.2 for the,folded dimer and the folded 
monomer. 
Antirod Antibodies  Affect Myosin Assembly 
Airfuge pelleting experiments were used to determine if the 
antirod antibodies could bind to preformed.myosin filaments, 
and if their binding prevented filament disassembly  in the 
presence of  MgATP. Without antibody, myosin filaments pel- 
leted in the absence of nucleotide, and were solubilized to 
the folded conformation upon addition of  MgATP (Fig. 7 B). 
In the presence of antibodies that mapped to ~e central por- 
tion of the rod ($2.1, $2.2, LMM.1, and LMM.2), antibody 
and myosin were found in the pelleted fraction both in the 
presence or absence of  MgATP (Fig. 7 C). These antibodies 
not only bind tightly  to myosin filaments, but block their dis- 
assembly to the folded conformation.  Electron microscopy 
confirmed that the antibody-myosin complex remained illa- 
mentous in the presence of MgATP (Trybus,  1989). 
Filament depolymerization  was promoted  by antibodies 
that bind close to the COOH terminus of the rod (LMM.3 
and LMM.4). In the absence of MgATP, binding of LMM.4 
solubilized approximately half the myosin (Fig. 7 A). Anti- 
body binding to the pelleted filaments was minimal. Metal- 
shadowed images showed that myosin with LMM.4 bound 
to the tail was still able to assume the folded conformation. 
In the presence of  antibody 10S.1, some filaments also disas- 
sembled.  Depolymerization  probably  occurs  via antibody 
binding to the monomer in equilibrium  with polymer, fol- 
lowed by filament disassembly to reestablish the monomer 
pool of antibody-free molecules. 
Discussion 
Among the monoclonal antibodies described here, two are 
especially  unusual  in  their ability  to distinguish  between 
conformational states  of smooth muscle myosin. Antibody 
10S.l, localized at the hairpin bend of the folded myosin 
monomer,  has a much higher affinity  for folded than ex- 
tended myosin. The ability  to generate an antibody against 
this  structural  state  provides direct  evidence that  the confor- 
mation of the rod is different  in the folded and extended 
forms of myosin. If  a hingelikc region that  underwent con- 
stant  bending existed  in  the rod, it  would be unlikely that  an 
antibody with this  specificity  could have been produced. In 
The Journal of Cell Biology, Volume 109,  1989  2882 Figure 3. Mapping  of  epitopes by electron  microscopy.  Metal-shadowed  images  of  antihead  antibodies  bound to myosin:  (A) SI.3, (B) SI.4, 
(C) SI.1, and (D) SI.2. Both SI.3 and S1.4 bind at the head/rod  junction. Arrows point to antibody. Antirod  antibodies: (E) $2.1, (F) $2.2, 
(G) LMM.1, (H) LMM.2, (I) LMM.3,  and (J) LMM.4. (K) 10S.1 binds at the HMM/LMM  hinge  where  the myosin  bends when  it assumes 
the folded conformation. Bar, 50 nm. 
agreement with these findings, secondary structure calcula- 
tions based on the gizzard rod sequence show no obvious in- 
terruptions  in the or-helix in the regions where the myosin 
rod folds (Yanagisawa et al.,  1987). 
Antibody $2.2, which binds at the COOH-terminal end of 
$2,  strongly favors the extended form of myosin, suggest- 
ing that the conformation  of this region may also be per- 
turbed upon formation of the nearby bend in the rod.  The 
change must be quite localized; however, because antibodies 
LMM.1  and $2.1, which also map near the HMM/LMM 
hinge, have equal affinities for folded and extended myosin. 
Conformation-specific  antibodies are uncommon. One well- 
known example is the collection of antibodies  specific for 
left-handed Z-DNA, which have been useful in determining 
the natural occurrence of  this form of the double helix (Lafer 
et al., 1981). Another example is a monoclonal antibody that 
binds to the calcium]calmodulin/phosphodiesterase complex, 
but not to phosphodiesterase  or calmodulin alone (Hansen 
and Beavo, 1982). A number of metal ion-dependent anti- 
body-antigen reactions have also been reported,  including 
antibodies against the prothrombin-calcium complex (Tai et 
al., t980), and against skeletal myosin light chain 2 (Shimizu 
et al.,  1985). 
Metal ion--dependent  antibody-antigen reactions were also 
observed here: beth dephosphorylated  and phosphorylated 
myosin required divalent cations to bind to antibody S1.3 or 
S1.4. Changes induced in the neck region by regulatory light 
chain phosphorylation thus appear to be distinct from those 
associated with metal binding to the light chain. Consistent 
with this observation,  the actin-activated ATPase of phos- 
phorylated myosin can be further increased in the presence 
of calcium, presumably due to metal ion binding to the non- 
specific calcium-magnesium sites on the regulatory  light 
chain (Chacko and Rosenfeld,  1982). Only myosin species 
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Figure 4. Localization of antibody 10S.1 to the HMM/LMM hinge.  O  m 
(A) Antibody 10S.I reacted with cross-linked folded myosin (o),  >. 
rod (a), and extended myosin (o), but not with HMM (ra), LMM  (:3 
(-), or SI (A). Reaction with neither HMM or LMM suggested  O  m 
that the epitope for this antibody was located at the hinge region 
between these two subfragments. The degree to which the rod  Z 
reacted with antibody lOS.1 by direct ELISA was variable. By soln-  < 
t--  tion competition  ELISA, however, rod and extended  myosin  showed  Z 
similar weak reactions. (B) Reactivity of antibody 10S.1 with myo-  m  O  sin was progressively lost as whole myosin was digested with chy-  n- 
motrypsin to HMM and LMM. 
with an intact neck region required metal ions for antibody 
binding; binding of SI to these antibodies was divalent cation 
independent. In a similar fashion, light-chain phosphoryla- 
tion only regulates the activity of those species that contain 
an intact head/rod junction. 
In addition to detecting changes in myosin conformations, 
the antirod antibodies could also stabilize myosin structural 
states. Four antibodies with epitopes in the central portion 
of therod ($2.1, $2.2, LMM.1, and LMM.2) bind tightly to 
synthetic filaments and block their disassembly to the folded 
monomer in the presence of MgATE The stabilization is 
probably due to a  physical cross-linking between myosin 
molecules in the filament. Alternatively, antibody binding 
could induce a change in the myosin that mimics phosphory- 
lation, although only modifications  to the head have been ob- 
served to have this effect (Nath et al.,  1986). 
LMM.3 and LMM.4, whose epitopes are located within 
the terminal one-third of the rod, depOlymerize smooth mus- 
cle myosirt filaments. The effect of these antibodies on poly- 
merization is consistent with the observation that the COOH- 
terminal region of the rod is important for filament assembly 
in a number of myosins. The aggregation of skeletal LMM 
at low ionic strength is due to a small region located '~15-20 
nm from the COOH terminus of the skeletal muscle rod 
(Nyitray et al., 1983). A larger, 20-nm COOH-terminal seg- 
ment, which overlaps the region responsible for insolubility 
in skeletal myosin, appears to play a role in intermolecular 
interactions between smooth muscle myosin rods (Cross and 
Vandekerckhove, 1986). The antibody with the greatest dis- 
assembling effect, LMM.4, binds within this region of the 
smooth muscle myosin tail. Although Dictyostelium myosin 
has a longer tail than smooth or skeletal myosin, the region 
responsible for aggregation was mapped to a similar region 
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Figure 5. Antibodies show  preferential reaction with myosin confor- 
mational states. Solution competition ELISAs were used to deter- 
mine the relative affinities of the antibodies for 10S folded (e) or 
6S extended (o) myosin. A constant am~mt of antibody was in- 
cubated with increasing concentrations of myosin; free antibody 
was detected by binding to a solid-phase antigen. The more the 
curve is displaced  to the left, the stronger the binding between  anti- 
body and antigen. (A) Antibody 10S.I binds 100-fold more strongly 
to folded myosin in 0.1 M KCI than to extended myosin in 0.5 M 
KCI. The fight panel shows that if the conformation is fixed in the 
folded state  by cross-linking, there is no ionic strength dependence 
of binding (0.1  M  KC1, ,,; 0.5 M KCI, n). The myosin concentra- 
tion at whichS0%  inhibition was achieved  was the same  for native 
and cross-linked folded myosin. (B) Antibody  $2.2 shows com- 
plementary behavior to antibody 10S.l; i.e., much tighter binding 
to extended than to folded myosin. (C) Antibody  LMM.I binds 
equally well to folded and extended myosin. Conditions:  10 mM 
KP~, pH 7.5, 0.1  or 0.5 M  KCI, 5 mM  MgCI2,  1 mM EGTA, 
1 mM DTT,  1 mM NAN3, 1 mM MgATE 
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Figure 6. Relative affinities of conformation-specific antibodies for 
myosin as a function of salt.  Relative affinities were determined 
from midpoints of competition curves such as those shown in Fig. 
5. The arrows at the top of the figure indicate salt concentrations 
where myosin is a folded dimer (15S), a folded monomer 00S), or 
an extended monomer (6S) (see Trybus and Lowey [1984] for the 
complete curve of how conformation varies with salt). The binding 
of 10S.1 (o) to folded myosin is high at low salt, and gets much 
weaker in the range of salt concentrations where the myosin un- 
folds. Antibody $2.2 (A) binds appreciably only at >0.3 M KC1, 
where myosin is extended. The binding of LMM.I (n) to myosin 
is conformation and salt independent. Conditions: as in legend to 
Fig. 5. 
Figure 7. Effect of antirod antibodies on myosin filament stability. 
Antibody-filament complexes were pelleted in the presence or ab- 
sence of MgATE In each panel, the lanes show starting material, 
supernatant, and pellet in the absence of MgATP, and supernatant 
and pellet in the presence of  MgATP. (A) LMM.4 and LMM.3 (data 
not shown) depolymerize filaments; myosin is found in the supema- 
tant even in the absence of nucleotide. (B) Without antibody, myo- 
sin is filamentous and pellets. Upon addition of  MgATP, the myosin 
is solubilized to the folded form and is found in the supernatant. 
(C) LMM.1, as well as $2.1, $2.2, and LMM.2 (data not shown), 
bind to myosin filaments and block their disassembly in the pres- 
ence of nucleotide. Conditions:  10 mM imidazole, pH 7, 0.15 M 
KCI, 5 mM MgCI2, 1 mM EGTA. 
with respect to the head/rod  junction (Pagh et al., 1984). An- 
tibodies  against  this  region  also  inhibit  polymerization, 
while an antibody against the very tip of the long tail only 
abolished antiparallel  interactions,  and unipolar filaments 
were formed (Peltz et al.,  1985; Pagh and Gerisch,  1986). 
In Acanthamoeba  myosin II, which has a short, 89-nm rod, 
proteolytic removal of 12-13 nm of the tail abolished assem- 
bly (Knznicki et al.,  1985), as did antibody binding to the 
tip of the tail (Kiehart and Pollard,  1984). 
The epitope for antibody LMM.4, which binds at the tip 
of the  gizzard  myosin tail,  must  be  near the  nonhelical, 
proline-containing tailpiece.  Smooth muscle myosins from 
gizzard (Yanagisawa et al., 1987), rabbit uterus (Nagai et al., 
1988),  and  the mollusc Mytilus  edulis  (Castellani  et al., 
1988) all contain such a  region. Only with Acanthamoeba 
myosin II (Hammer et al.,  1987), however, has a functional 
role been assigned to this nonhelical region. Phosphoryla- 
tion of three serines per chain in the tailpiece inhibits actin- 
activated ATPase activity, but does not change the state of  as- 
sembly of the myosin (Collins et al.,  1982; Knznicki et al., 
1983; Atkinson and Koru, 1987). Phosphorylation of the tail- 
piece of the molluscan smooth muscle myosin, in contrast, 
favors filament disassembly to the folded monomer (Castel- 
lani and Cohen, 1987). The heavy chain of vertebrate smooth 
muscle myosin can be phosphorylated, but the effect of this 
modification on assembly and the location of the phosphory- 
lation site have not been determined (Kawamoto and Adel- 
stein,  1988). 
The ability of  the monoelonal antibodies described here to 
alter the state of myosin without changing solvents allows the 
relationship between enzymatic activity, light chain phos- 
phorylation, and smooth muscle myosin conformation to be 
further investigated.  In  the accompanying paper (Trybus, 
1989), the actin-activated activity of dephosphorylated illa- 
ments, a state that is present in relaxed smooth muscle cells 
but difficult to stabilize in vitro, was measured in a  more 
physiological solvent than was previously possible. 
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